Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

SIRT7 inhibitor 97491

  Cat. No.:  DC40782   Featured
Chemical Structure
1807758-81-1
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway..
Cas No.: 1807758-81-1
Chemical Name: SIRT7 inhibitor 97491
SMILES: NC1=CC(NC2=NC=C(C3=CC=C(Cl)C=C3)O2)=CC=C1
Formula: C15H12ClN3O
M.Wt: 285.73
Purity: >98%
Sotrage: 4°C, protect from light*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publication: [1]. Ji-Hye Kim, et al. Identification of a Novel SIRT7 Inhibitor as Anticancer Drug Candidate. Biochem Biophys Res Commun. 2019 Jan 8;508(2):451-457.
Description: SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway.[1].
Target: SIRT7:325 nM (IC50)
In Vivo: SIRT7 inhibitor 97491 (2 mg/kg; intraperitoneally injected; for 3 weeks, except on weekends) inhibits tumor growth in xenograft mice[1]. Animal Model: Balb/c nude mice (18-20 g; 6-8 weeks old) with MES-SA cells[1] Dosage: 2 mg/kg Administration: Intraperitoneally injected; for 3 weeks, except on weekends. Result: Inhibited cancer growth in vivo.
In Vitro: SIRT7 inhibitor 97491 (1-10 μM) reduces cell growth in MES-SA cells, without causing cytotoxicity in HEK293 cells[1]. Cell Proliferation Assay[1] Cell Line: Human uterine sarcoma MES-SA cells Concentration: 1, 5, 10 μM Incubation Time: 72 hours Result: Led to more than 50% decrease in cell proliferation at concentrations of 5 and 10 μM. Cell Cytotoxicity Assay[1] Cell Line: Human embryonic kidney cell line HEK293 cells Concentration: 1, 5, 10 μM Incubation Time: 24 hours Result: HEK293 cells were almost unaffected.
References: [1]. Ji-Hye Kim, et al. Identification of a Novel SIRT7 Inhibitor as Anticancer Drug Candidate. Biochem Biophys Res Commun. 2019 Jan 8;508(2):451-457.
MSDS
TITLE DOWNLOAD
MSDS_23795_DC40782_1807758-81-1
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC73350 JYQ-42 JYQ-42 is a potent, selective SIRT6 allosteric inhibitor, effectively inhibits SIRT6 deacetylation with IC50 of 2.33 uM, inhibits the deacetylation activity of SIRT6 in pancreatic cancer cell lines.
DC71745 Sirtuin modulator 2 Sirtuin modulator 2 (Compound 132) is a sirtuin modulator with an ED50 equal or less than 50 μM.
DC71744 MIND4-19 MIND4-19 is a potent SIRT2 inhibitor with an IC50 value of 7.0 μM. MIND4-19 can be used for researching Huntington's disease.
DC40849 SIRT1-IN-1 SIRT1-IN-1 is a selective SIRT1 inhibitor with an IC50 of 0.205 μM. SIRT1-IN-1 inhibits SIRT2 with an IC50 of 11.5 μM. SIRT1-IN-1, a indole, is a cytomegalovirus (CMV) inhibitors and has antiviral activity.
DC40782 SIRT7 inhibitor 97491 SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway..
DC11213 E1231 E1231 (E-1231) is a small molecule SIRT1 activator with EC50 of 0.83 uM, interactes with recombinant human SIRT1 protein and deacetylated liver X receptor-alpha (LXRα).
X